MetLife Inc

MET remains in a Stage 2 advancing phase with bullish medium- and long-term biases confirmed by rising EMAs and successive higher highs and lows. Price is holding just above the rising 9- and 20-day EMAs near the $95–96 support zone, with no signs of exhaustion and RSI in neutral territory. Short-term conditions favor immediate participation at dynamic support, targeting a continuation toward new highs, while a breakdown below EMAs would warrant deferment.

• ↑Q2 adjusted earnings $1.6B up 15% YoY, EPS $1.09 (+20%)
• ↑Adjusted ROE reached 17%, underscoring strong profitability
• ↓Negative growth and revision factors imply turnover challenges